This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aclaris Therapeutics’s 8K filing here.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
See Also
- Five stocks we like better than Aclaris Therapeutics
- What Are Dividend Achievers? An Introduction
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Best Stocks Under $10.00
- Applied Materials Market Capitulates: Now is the Time to Buy
- Market Cap Calculator: How to Calculate Market Cap
- 3 Ultra-High Dividend Yield Stocks for the New Year
